ASCO Annual Meeting: Melanoma

Articles

Ajay K. Nooka, MD, MPH, FACP discussed the clinical benefits of belantamab mafodotin in combination with bortezomib/dexamethasone to treat multiple myeloma.

ASCO Expert Discusses Clinical Benefit of Combination for Relapsed/Refractory Multiple Myeloma

Cancer Network spoke with Anna Pavlick, MD, of NYU Langone Health, on the results of a phase II study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared with Montanide.

Dr. Anna Pavlick on Dendritic Cells vs Montanide in Melanoma Patients in Remission

Videos

Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan Kettering Cancer Center, about pursuing adjuvant immunotherapy for patients with melanoma.

Dr. Paul Chapman on the Choice to Pursue Adjuvant Immunotherapy for Melanoma Patients

Cancer Network spoke with Hussein Tawbi, MD, PhD, of MD Anderson Cancer Center, about the efficacy and safety of the combination of nivolumab plus ipilimumab in patients with symptomatic melanoma brain metastases.

Dr. Hussein Tawbi on Efficacy and Safety Results From the CheckMate 204 Melanoma Trial

Cancer Network spoke with Allison Betof Warner, MD, PhD, of Memorial Sloan Kettering Cancer Center, about long-term outcomes and responses to retreatment in patients with melanoma receiving anti-PD1 therapy.

Dr. Allison Betof Warner on Outcomes With Anti-PD1 Therapy in Melanoma

Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan-Kettering Cancer Center about strategies and research surrounding optimized targeted therapy in melanoma.

Dr. Paul B. Chapman on Optimizing Targeted Therapy in Melanoma

Cancer Network spoke with Hussein Abdul-Hassan Tawbi, MD, PhD, on the results of a phase II study of oral azacitidine in combination with pembrolizumab in metastatic melanoma.

Dr. Hussein Abdul-Hassan Tawbi on Oral Azacitidine Plus Pembrolizumab in Metastatic Melanoma

Cancer Network spoke with Anna Pavlick, MD, of NYU's Perlmutter Cancer Center, regarding whether there is one correct answer to front-line therapy for the treatment of advanced melanoma.

Dr. Anna Pavlick on Options for First-Line Therapy in Late-Stage Melanoma

Cancer Network spoke with Thomas Gajewski, MD, PhD, of the University of Chicago Medical Center, about analyzing the tumor microenvironment to guide immunotherapy in melanoma.

Dr. Thomas Gajewski on Analyzing the Tumor Microenvironment to Guide Immunotherapy in Melanoma

Cancer Network spoke with Janice M. Mehnert, MD, of Rutgers Cancer Institute, about the use of immunotherapy vs BRAF/MEK inhibitors in the adjuvant setting for melanoma.

ASCO Annual Meeting: Melanoma | Conference